Clinical Trial Update: A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) [Phase 3]

View source ↗

Summary

A Canadian Phase 3 open-label study (ACCLAIM) evaluated adding adalimumab to inadequate therapy for psoriatic arthritis, assessing safety and effectiveness. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED